526269

- The Board approved the Unaudited Consolidated Financial Results for the quarter ended June 30, 2026. - Consolidated Operating Revenue for Q1 FY27 was ₹925.69 Lacs. - Consolidated EBITDA for Q1 FY27 was ₹114.19 Lacs (12.34% margin). - Consolidated PAT for Q1 FY27 was ₹94.16 Lacs. - Year-on-year consolidated comparison data for the quarter ended June 30, 2025, is not available in the provided consolidated financial table.

- The 34th Annual General Meeting (AGM) of Crestchem Limited was held on August 6, 2026, via Video Conference (VC) from 12:15 PM to 12:40 PM. - A summary of proceedings and the Scrutinizer's Report for remote e-voting (August 3-5, 2026) and e-voting at the AGM are submitted. - There were no qualifications, observations or adverse comments on the financial statements or audit reports. - The results of the voting will be declared within prescribed timelines.

- CRESTCHEM LIMITED filed Voting Results and Scrutinizer's Report for its AGM held on August 6, 2026. - All resolutions were approved with 100% votes in favour. - Resolutions included adoption of financial statements for FY ended March 31, 2026, and declaration of a final dividend of ₹1.50/- per equity share.

- Board Meeting scheduled for August 12, 2026, at 04:30 pm. - Agenda includes approving Q1 FY27 unaudited financial results. - Will also note a fine imposed by BSE for late submission of consolidated cash flow statement.

- The 34th Annual General Meeting (AGM) of Crestchem Limited was held on August 6, 2026, through video conferencing. - Remote e-voting commenced on August 3, 2026, and continued till August 5, 2026. - No qualifications, observations, or adverse comments were noted on the financial statements, Auditor's Report, or Secretarial Audit Report. - The voting results will be declared upon receipt of the Scrutinizer's Report.

- BSE imposed a fine of ₹1,06,200 on Crestchem Limited for late submission of the Consolidated Cash Flow Statement.- The company anticipates a waiver for the fine, stating no material financial impact.

- Board of Directors declared a dividend of 15% (₹1.50 per equity share) for FY 2025-26. - The record date for determining eligible shareholders for the dividend is Thursday, July 30, 2026.

- The Board announced the 34th Annual General Meeting (AGM) to be held on August 06, 2026. - Book closure for the AGM and dividend is from July 30, 2026, to August 06, 2026. - A dividend of Rs. 1.50 per share was declared, with the record date set as July 30, 2026.

- Crestchem Limited submitted a filing regarding the Escrow Payment Mechanism. - The company stated that the Escrow Payment Mechanism is not applicable as it does not maintain any of the specified escrow accounts (No Lien, Interest Payment, Sinking Fund, or General Account).

- Crestchem Limited submitted a filing regarding the Escrow Payment Mechanism. The company confirmed that it does not have any No Lien, Interest Payment, Sinking Fund, or General escrow accounts, thus the Escrow Payment Mechanism is not applicable to them.

- Annual Report for FY 2025-26 submitted. - Total Income: ₹25.52 Cr vs ₹21.52 Cr (▲18.6% YoY) - Net Profit: ₹2.71 Cr vs ₹2.73 Cr (▼0.7% YoY) - EPS: ₹9.04 vs ₹9.08 (▼0.4% YoY) - Final dividend of ₹1.50 (15%) per equity share declared for FY 2025-26. - Annual General Meeting (AGM) to be held on August 06, 2026.

- Standalone Revenue ₹10.23 Cr vs ₹7.23 Cr (▲41.38% YoY) - Standalone EBITDA ₹1.40 Cr vs ₹0.60 Cr (▲131.95% YoY) - Standalone PAT ₹1.10 Cr vs ₹0.61 Cr (▲80.82% YoY) - Standalone EBITDA Margin 13.67% vs 8.33% (▲534bps) - Board recommended a Final Dividend of ₹1.50 per Equity Share (15%) for the financial year 2025-26.

- The Board of Directors fixed August 06, 2026, as the date for the 34th Annual General Meeting. - Approved the Board of Directors' report, Corporate Governance report, and Management Discussion and Analysis Report for the 34th AGM. - Fixed book closure and Record Date for the payment of dividend for F.Y.2025-26.

- Trading window closed from July 01, 2026. - Reopens 48 hours after announcement of unaudited financial results for the quarter ended June 2026. - Applicable to designated persons, directors/KMP, and other designated employees.

- Board Meeting scheduled for July 04, 2026, at 12:15 PM. - Agenda includes fixing the 34th AGM date, approving various reports, and fixing the book closure/record date for F.Y. 2025-26 dividend payment.

- Standalone Operating Revenue for the quarter ended March 31, 2026 was ₹1,022.53 Lacs vs ₹723.20 Lacs in the prior year quarter (▲41.38% YoY) - Standalone EBITDA for the quarter ended March 31, 2026 was ₹139.81 Lacs vs ₹60.28 Lacs in the prior year quarter (▲131.95% YoY) - Standalone PAT for the quarter ended March 31, 2026 was ₹110.38 Lacs vs ₹61.04 Lacs in the prior year quarter (▲80.82% YoY) - Standalone EBITDA Margin expanded to 13.67% vs 8.33% in the prior year quarter (▲534 bps) - The Board recommended a Final Dividend of Rs. 1.50 per Equity Share (15%) for the financial year 2025-26. - Noted the formation of a new subsidiary, Oleo Biosciences Private Limited, in March 2026. - Approved an investment of up to ₹2.25 Crores in the subsidiary. - Reappointed three directors for a period of five years.

- Standalone Operating Revenue ₹10.23Cr vs ₹7.23Cr (▲41.39% YoY) - EBITDA ₹1.40Cr vs ₹0.60Cr (▲131.95% YoY) - PAT ₹1.10Cr vs ₹0.61Cr (▲80.82% YoY) - EBITDA Margin 13.67% vs 8.33% (▲534bps) - Board recommended a final dividend of ₹1.50 per equity share (15%) for FY 2025-26. - Noted the formation of a new subsidiary, Oleo Biosciences Private Limited, on March 31, 2026, with an approved investment of up to ₹2.25 Crores. - Approved the reappointment of Mr. Dipak Narendraprasad Patel, Mrs. Parul Dipak Patel, and Mrs. Tansi Nirmit Patel as directors for five-year terms.